1. Home
  2. ASTL vs PHVS Comparison

ASTL vs PHVS Comparison

Compare ASTL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Algoma Steel Group Inc.

ASTL

Algoma Steel Group Inc.

HOLD

Current Price

$4.51

Market Cap

408.2M

Sector

Industrials

ML Signal

HOLD

Logo Pharvaris N.V.

PHVS

Pharvaris N.V.

HOLD

Current Price

$24.72

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASTL
PHVS
Founded
1902
2015
Country
Canada
Switzerland
Employees
N/A
N/A
Industry
Steel/Iron Ore
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
408.2M
1.7B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ASTL
PHVS
Price
$4.51
$24.72
Analyst Decision
Buy
Analyst Count
0
9
Target Price
N/A
$39.44
AVG Volume (30 Days)
1.5M
534.0K
Earning Date
10-29-2025
11-12-2025
Dividend Yield
2.24%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,589,572,318.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.02
$11.51
52 Week High
$10.19
$29.80

Technical Indicators

Market Signals
Indicator
ASTL
PHVS
Relative Strength Index (RSI) 60.74 50.17
Support Level $4.33 $23.61
Resistance Level $4.75 $24.63
Average True Range (ATR) 0.25 2.02
MACD 0.07 -0.32
Stochastic Oscillator 77.78 25.27

Price Performance

Historical Comparison
ASTL
PHVS

About ASTL Algoma Steel Group Inc.

Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.

About PHVS Pharvaris N.V.

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Share on Social Networks: